Sandoz, which operates Europe’s last major end-to-end antibiotics manufacturing chain at its Kundl plant in Austria, has warned that below-cost imports from China of the active pharmaceutical ingredients (APIs) used to produce amoxicillin are threatening the EU’s capacity to manufacture essential medicines.
In a statement to Vital Signs, Sandoz said it had filed a draft anti-dumping complaint with the European Commission because the situation had reached “breaking point”, due to sustained below-cost pricing and clear market distortions putting Europe’s last major antibiotic manufacturer at risk.
The company says the complaint contains evidence of practices that appear to be incompatible with “fair, rules-based international trade”.
“Sandoz is not seeking….
